Skip to Content

29,672 Results Found

  • Article
  • Open Access
32 Citations
5,066 Views
13 Pages

c-Met-Specific Chimeric Antigen Receptor T Cells Demonstrate Anti-Tumor Effect in c-Met Positive Gastric Cancer

  • Chung Hyo Kang,
  • Yeongrin Kim,
  • Da Yeon Lee,
  • Sang Un Choi and ,
  • Heung Kyoung Lee and
  • Chi Hoon Park
  • + 1 author+ 0 author

16 November 2021

Chimeric antigen receptor (CAR) technology has been highlighted in recent years as a new therapeutic approach for cancer treatment. Although the impressive efficacy of CAR-based T cell adoptive immunotherapy has been observed in hematologic cancers,...

(This article belongs to the Section Cancer Immunology and Immunotherapy)
  • Article
  • Open Access
8 Citations
8,127 Views
14 Pages

Tackling CASMI 2012: Solutions from MetFrag and MetFusion

  • Christoph Ruttkies,
  • Michael Gerlich and
  • Steffen Neumann

5 August 2013

The task in the critical assessment of small molecule identification (CASMI) contest category 2 was to determine the identification of (initially) unknown compounds for which high-resolution tandem mass spectra were published. We focused on computer-...

(This article belongs to the Special Issue Small Molecule Identification beyond the Crystal Ball - Selected Papers from CASMI)
  • Article
  • Open Access
11 Citations
4,061 Views
18 Pages

Plasma Carotenoids and Polyphenols and Their Association with MetS: The Need for Nutritional Interventions

  • Agnieszka Białkowska,
  • Magdalena Górnicka,
  • Monika A. Zielinska-Pukos,
  • Ewelina Hallmann and
  • Jadwiga Hamulka

Metabolic syndrome (MetS) is characterized by increased pro-oxidative stress and a chronic inflammation state and their consequent alterations. Several studies have highlighted the protective effect of carotenoids and polyphenols in MetS patients. Th...

(This article belongs to the Special Issue Antioxidant Foods and Cardiometabolic Health - 2nd Edition)
  • Review
  • Open Access
13 Citations
3,952 Views
17 Pages

MET Oncogene Targeting for Cancer Immunotherapy

  • Andrea Maria Lombardi,
  • Dario Sangiolo and
  • Elisa Vigna

The MET receptor is one of the main drivers of ‘invasive growth’, a multifaceted biological response essential during embryonic development and tissue repair that is usurped by cancer cells to induce and sustain the malignant phenotype. M...

(This article belongs to the Special Issue Update on Immunotherapies for Cancer)
  • Review
  • Open Access
21 Citations
4,962 Views
14 Pages

Overview of Molecular Detection Technologies for MET in Lung Cancer

  • Carina Heydt,
  • Michaela Angelika Ihle and
  • Sabine Merkelbach-Bruse

26 May 2023

MET tyrosine kinase receptor pathway activation has become an important actionable target in solid tumors. Aberrations in the MET proto-oncogene, including MET overexpression, the activation of MET mutations, MET mutations that lead to MET exon 14 sk...

(This article belongs to the Special Issue Roles of MET in Cancer Development and Treatment)
  • Article
  • Open Access
6 Citations
5,539 Views
15 Pages

Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLC

  • Guang-Ling Jie,
  • Lun-Xi Peng,
  • Mei-Mei Zheng,
  • Hao Sun and ,
  • Song-Rong Wang,
  • Si-Yang Maggie Liu,
  • Kai Yin,
  • Zhi-Hong Chen,
  • Hong-Xia Tian and
  • Yi-Long Wu
  • + 10 authors+ 5 authors

1 January 2023

MET inhibitors have shown promising efficacy for MET-dysregulated non-small cell lung cancer (NSCLC). However, quite a few patients cannot benefit from it due to the lack of powerful biomarkers. This study aims to explore the potential role of plasma...

(This article belongs to the Special Issue Roles of MET in Cancer Development and Treatment)
  • Article
  • Open Access
2 Citations
2,634 Views
12 Pages

c-Met+ Cytotoxic T Lymphocytes Exhibit Enhanced Cytotoxicity in Mice and Humans In Vitro Tumor Models

  • Mahdia Benkhoucha,
  • Ngoc Lan Tran,
  • Isis Senoner,
  • Gautier Breville and ,
  • Hajer Fritah,
  • Denis Migliorini,
  • Valérie Dutoit and
  • Patrice H. Lalive
  • + 3 authors+ 0 author

23 November 2023

CD8+ cytotoxic T lymphocytes (CTLs) play a crucial role in anti-tumor immunity. In a previous study, we identified a subset of murine effector CTLs expressing the hepatocyte growth factor (HGF) receptor, c-Met (c-Met+ CTLs), that are endowed with enh...

(This article belongs to the Special Issue Editorial Board Members' Collection Series: Cell Biology and Pathology)
  • Review
  • Open Access
1 Citations
1,858 Views
23 Pages

MET pathway alterations have evolved from a niche translational interest into one of the most clinically actionable axes in non-small cell lung cancer (NSCLC). Three biologically distinct lesions—MET exon 14 (METex14) skipping mutations, focal...

(This article belongs to the Section Materials Science)
  • Article
  • Open Access
13 Citations
6,329 Views
23 Pages

Therapeutic Efficacy of ABN401, a Highly Potent and Selective MET Inhibitor, Based on Diagnostic Biomarker Test in MET-Addicted Cancer

  • Jooseok Kim,
  • Kyung Eui Park,
  • Yoo-Seong Jeong,
  • YeongMun Kim and ,
  • Hayeon Park,
  • Ji-Hye Nam,
  • Kyungsoo Jung,
  • Woo Sung Son,
  • Hun Soon Jung and
  • Young Kee Shin
  • + 14 authors+ 9 authors

15 June 2020

The receptor tyrosine kinase c-MET regulates processes essential for tissue remodeling and mammalian development. The dysregulation of c-MET signaling plays a role in tumorigenesis. The aberrant activation of c-MET, such as that caused by gene amplif...

  • Article
  • Open Access
11 Citations
5,334 Views
13 Pages

MET Expression Level in Lung Adenocarcinoma Loosely Correlates with MET Copy Number Gain/Amplification and Is a Poor Predictor of Patient Outcome

  • Wei Yin,
  • Ming Guo,
  • Zhenya Tang,
  • Gokce A. Toruner and ,
  • Joanne Cheng,
  • L. Jeffrey Medeiros and
  • Guilin Tang
  • + 2 authors+ 0 author

14 May 2022

MET amplification has been associated with shorter survival in cancer patients, however, the potential correlation of MET overexpression with either MET amplification or patient outcome is controversial. The aim of this study was to address these que...

(This article belongs to the Topic The Role of Transmembrane Mucins in Lung Diseases)
  • Guidelines
  • Open Access
7 Citations
7,488 Views
25 Pages

Canadian Consensus Recommendations on the Management of MET-Altered NSCLC

  • Parneet K. Cheema,
  • Shantanu O. Banerji,
  • Normand Blais,
  • Quincy S.-C. Chu and ,
  • Patrice Desmeules,
  • Rosalyn A. Juergens,
  • Natasha B. Leighl,
  • Brandon S. Sheffield,
  • Paul F. Wheatley-Price and
  • Barbara L. Melosky
  • + 5 authors+ 0 author

9 November 2021

In Canada, the therapeutic management of patients with advanced non-small cell lung cancer (NSCLC) with rare actionable mutations differs between provinces, territories, and individual centres based on access to molecular testing and funded treatment...

  • Review
  • Open Access
23 Citations
8,845 Views
23 Pages

29 April 2025

Background: Recent research has increasingly highlighted alterations in the proto-oncogene MET, whose abnormal activation has been implicated in multiple cancers. MET encodes c-MET, a receptor tyrosine kinase critical for cellular growth, survival, a...

(This article belongs to the Section Molecular Cancer Biology)
  • Review
  • Open Access
24 Citations
6,875 Views
11 Pages

26 April 2022

Dysregulation of the MET tyrosine kinase receptor is a known oncogenic driver, and multiple genetic alterations can lead to a clinically relevant oncogenesis. Currently, a number of drugs targeting MET are under development as potential therapeutics...

(This article belongs to the Special Issue Roles of MET in Cancer Development and Treatment)
  • Article
  • Open Access
4 Citations
3,940 Views
14 Pages

Retrospective Evaluation on the Use of a New Polysaccharide Complex in Managing Paediatric Type 1 Diabetes with Metabolic Syndrome (MetS)

  • Stefano Stagi,
  • Valeria Papacciuoli,
  • Daniele Ciofi,
  • Barbara Piccini and ,
  • Giovanni Farello,
  • Sonia Toni,
  • Marta Ferrari and
  • Francesco Chiarelli
  • + 3 authors+ 0 author

7 October 2021

Background: Children and adolescents affected by type 1 diabetes have an increased risk of being overweight or obese and of suffering from cardiometabolic symptoms. Aims: To retrospectively evaluate the effects of a new complex of polysaccharide macr...

(This article belongs to the Section Nutrition and Diabetes)
  • Article
  • Open Access
4 Citations
3,613 Views
20 Pages

Correlation of MET-Receptor Overexpression with MET Gene Amplification and Patient Outcome in Malignant Mesothelioma

  • Eric Santoni-Rugiu,
  • Maya Jeje Schuang Lü,
  • Jan Nyrop Jakobsen,
  • Linea Cecilie Melchior and ,
  • Jesper Ravn and
  • Jens Benn Sørensen
  • + 1 author+ 0 author

28 November 2021

Thanks to clinically newly introduced inhibitors of the mesenchymal–epithelial transition (MET) receptor tyrosine-kinase, MET-gene copy number gain/amplification (MET-GCNG/GA) and increased expression of the MET protein are considered very prom...

(This article belongs to the Special Issue Molecular Players in Diagnostics and Therapeutics of Malignant Pleural Mesothelioma)
  • Review
  • Open Access
20 Citations
6,604 Views
14 Pages

14 September 2023

The MET gene plays a vital role in cellular proliferation, earning it recognition as a principal oncogene. Therapies that target MET amplification have demonstrated promising results both in preclinical models and in specific clinical cases. A signif...

(This article belongs to the Special Issue Roles of MET in Cancer Development and Treatment)
  • Review
  • Open Access
20 Citations
7,009 Views
17 Pages

Met in Urological Cancers

  • Yasuyoshi Miyata,
  • Akihiro Asai,
  • Kensuke Mitsunari,
  • Tomohiro Matsuo and ,
  • Kojiro Ohba,
  • Yasushi Mochizuki and
  • Hideki Sakai
  • + 2 authors+ 0 author

16 December 2014

Met is a tyrosine kinase receptor that is considered to be a proto-oncogene. The hepatocyte growth factor (HGF)-Met signaling system plays an important role in tumor growth, invasion, and metastasis in many types of malignancies. Furthermore, Met ex...

(This article belongs to the Special Issue MET in Cancer)
  • Article
  • Open Access
3 Citations
3,030 Views
16 Pages

NGS Sequencing Reveals New UCP1 Gene Variants Potentially Associated with MetS and/or T2DM Risk in the Polish Population—A Preliminary Study

  • Anna Andrzejczak,
  • Agata Witkowicz,
  • Dorota Kujawa,
  • Damian Skrypnik and ,
  • Monika Szulińska,
  • Paweł Bogdański,
  • Łukasz Łaczmański and
  • Lidia Karabon
  • + 3 authors+ 0 author

24 March 2023

The number of people suffering from metabolic syndrome (MetS) including type 2 diabetes (T2DM), hypertension, and obesity increased over 10 times through the last 30 years and it is a severe public health concern worldwide. Uncoupling protein 1 (UCP1...

(This article belongs to the Section Human Genomics and Genetic Diseases)
  • Review
  • Open Access
26 Citations
7,204 Views
25 Pages

MET in Non-Small-Cell Lung Cancer (NSCLC): Cross ‘a Long and Winding Road’ Looking for a Target

  • Gianluca Spitaleri,
  • Pamela Trillo Aliaga,
  • Ilaria Attili,
  • Ester Del Signore and ,
  • Carla Corvaja,
  • Chiara Corti,
  • Jacopo Uliano,
  • Antonio Passaro and
  • Filippo de Marinis
  • + 4 authors+ 0 author

28 September 2023

Non-Small-Cell Lung Cancer (NSCLC) can harbour different MET alterations, such as MET overexpression (MET OE), MET gene amplification (MET AMP), or MET gene mutations. Retrospective studies of surgical series of patients with MET-dysregulated NSCLC h...

(This article belongs to the Special Issue Cancer Therapy: Where We Are and Where We Need to Go)
  • Article
  • Open Access
4 Citations
3,266 Views
13 Pages

Capmatinib and savolitinib, selective MET inhibitors, are widely used to treat various MET-positive cancers. In this study, we aimed to determine the effects of these inhibitors on MET-amplified gastric cancer (GC) cells. Methods: After screening 37...

(This article belongs to the Section Molecular Oncology)
  • Article
  • Open Access
19 Citations
4,796 Views
17 Pages

Targeting HGF/c-Met Axis Decreases Circulating Regulatory T Cells Accumulation in Gastric Cancer Patients

  • Juliette Palle,
  • Laure Hirsch,
  • Alexandra Lapeyre-Prost,
  • David Malka and ,
  • Morgane Bourhis,
  • Simon Pernot,
  • Elie Marcheteau,
  • Thibault Voron,
  • Florence Castan and
  • Magali Terme
  • + 14 authors+ 9 authors

5 November 2021

Elucidating mechanisms involved in tumor-induced immunosuppression is of great interest since it could help to improve cancer immunotherapy efficacy. Here we show that Hepatocyte Growth Factor (HGF), a pro-tumoral and proangiogenic factor, and its re...

(This article belongs to the Special Issue Tumor Vasculature and Immunity in Cancer)
  • Review
  • Open Access
11 Citations
6,845 Views
15 Pages

Cyclic Peptide-Based Biologics Regulating HGF-MET

  • Hiroki Sato,
  • Ryu Imamura,
  • Hiroaki Suga,
  • Kunio Matsumoto and
  • Katsuya Sakai

27 October 2020

Using a random non-standard peptide integrated discovery system, we obtained cyclic peptides that bind to hepatocyte growth factor (HGF) or mesenchymal-epithelial transition factor. (MET) HGF-inhibitory peptide-8 (HiP-8) selectively bound to two-chai...

(This article belongs to the Special Issue Hepatocyte Growth Factor (HGF), II)
  • Article
  • Open Access
28 Citations
5,918 Views
18 Pages

Detection of MET Alterations Using Cell Free DNA and Circulating Tumor Cells from Cancer Patients

  • Patricia Mondelo-Macía,
  • Carmela Rodríguez-López,
  • Laura Valiña,
  • Santiago Aguín and ,
  • Luis León-Mateos,
  • Jorge García-González,
  • Alicia Abalo,
  • Oscar Rapado-González,
  • Mercedes Suárez-Cunqueiro and
  • Rafael López-López
  • + 13 authors+ 8 authors

24 February 2020

MET alterations may provide a potential biomarker to evaluate patients who will benefit from treatment with MET inhibitors. Therefore, the purpose of the present study is to investigate the utility of a liquid biopsy-based strategy to assess MET alte...

(This article belongs to the Special Issue Liquid Biopsy)
  • Review
  • Open Access
8 Citations
6,870 Views
19 Pages

The MET Oncogene: An Update on Targeting Strategies

  • Simona Gallo,
  • Consolata Beatrice Folco and
  • Tiziana Crepaldi

2 November 2024

The MET receptor, commonly known as HGF (hepatocyte growth factor) receptor, is a focus of extensive scientific research. MET has been linked to embryonic development, tissue regeneration following injury, tumorigenesis, and cancer metastasis. These...

(This article belongs to the Section Pharmacology)
  • Review
  • Open Access
35 Citations
11,555 Views
16 Pages

MET and Small-Cell Lung Cancer

  • Francesco Gelsomino,
  • Giulio Rossi and
  • Marcello Tiseo

13 October 2014

Small-cell lung cancer (SCLC) is one of the most aggressive lung tumors. The majority of patients with SCLC are diagnosed at an advanced stage. This tumor type is highly sensitive to chemo-radiation treatment, with very high response rates, but invar...

(This article belongs to the Special Issue MET in Cancer)
  • Review
  • Open Access
30 Citations
15,308 Views
39 Pages

12 August 2014

Met is the receptor of hepatocyte growth factor (HGF), a cytoprotective cytokine. Disturbing the equilibrium between Met and its ligand may lead to inappropriate cell survival, accumulation of genetic abnormalities and eventually, malignancy. Abnorma...

(This article belongs to the Special Issue MET in Cancer)
  • Feature Paper
  • Review
  • Open Access
3 Citations
8,380 Views
33 Pages

MET-Targeting Anticancer Drugs—De Novo Design and Identification by Drug Repurposing

  • Kenneth Kin-Wah To,
  • Kwong-Sak Leung and
  • William Chi-Shing Cho

The Met protein is a cell surface receptor tyrosine kinase predominantly expressed in epithelial cells. Aberrant regulation of MET is manifested by numerous mechanisms including amplification, mutations, deletion, fusion of the MET proto-oncogene, an...

(This article belongs to the Section Preclinical Research)
  • Review
  • Open Access
8 Citations
6,932 Views
19 Pages

Clinical Development of c-MET Inhibition in Hepatocellular Carcinoma

  • Joycelyn J. X. Lee,
  • Jack J. Chan and
  • Su Pin Choo

28 October 2015

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death. In patients with advanced or unresectable HCC, there are few treatment options. Conventional chemotherapy has limited benefits. Sorafenib, a multi-kinase inhibitor, improve...

(This article belongs to the Special Issue Targeted Therapy of Hepatocellular Carcinoma: Present and Future)
  • Article
  • Open Access
1 Citations
2,555 Views
17 Pages

Genetic Ablation of the MET Oncogene Defines a Crucial Role of the HGF/MET Axis in Cell-Autonomous Functions Driving Tumor Dissemination

  • Chiara Modica,
  • Marco Cortese,
  • Francesca Bersani,
  • Andrea Maria Lombardi and ,
  • Francesca Napoli,
  • Luisella Righi,
  • Riccardo Taulli,
  • Cristina Basilico and
  • Elisa Vigna
  • + 4 authors+ 0 author

13 May 2023

Cancer cell dissemination is sustained by cell-autonomous and non-cell-autonomous functions. To disentangle the role of HGF (Hepatocyte Growth Factor) and MET ligand/receptor axis in this complex process, we genetically knocked out the MET gene in ca...

(This article belongs to the Special Issue The Biological Mechanism of Cancer Proliferation and Metastasis)
  • Review
  • Open Access
9 Citations
4,519 Views
23 Pages

21 September 2023

The MET proto-oncogene encodes a pivotal tyrosine kinase receptor, binding the hepatocyte growth factor (HGF, also known as scatter factor, SF) and governing essential biological processes such as organogenesis, tissue repair, and angiogenesis. The p...

(This article belongs to the Section Molecular Cancer Biology)
  • Article
  • Open Access
4 Citations
3,930 Views
15 Pages

Molecular Engineering Strategies Tailoring the Apoptotic Response to a MET Therapeutic Antibody

  • Chiara Modica,
  • Simona Gallo,
  • Cristina Chiriaco,
  • Martina Spilinga and ,
  • Paolo Maria Comoglio,
  • Tiziana Crepaldi,
  • Cristina Basilico and
  • Elisa Vigna
  • + 3 authors+ 0 author

21 March 2020

The MET oncogene encodes a tyrosine kinase receptor involved in the control of a complex network of biological responses that include protection from apoptosis and stimulation of cell growth during embryogenesis, tissue regeneration, and cancer progr...

(This article belongs to the Special Issue Cell Death in Cancer)
  • Review
  • Open Access
96 Citations
13,517 Views
13 Pages

Targeting MET Amplification as a New Oncogenic Driver

  • Hisato Kawakami,
  • Isamu Okamoto,
  • Wataru Okamoto,
  • Junko Tanizaki and ,
  • Kazuhiko Nakagawa and
  • Kazuto Nishio
  • + 1 author+ 0 author

22 July 2014

Certain genetically defined cancers are dependent on a single overactive oncogene for their proliferation and survival, a phenomenon known as “oncogene addiction”. A new generation of drugs that selectively target such “driver oncogenes” manifests a...

(This article belongs to the Special Issue MET in Cancer)
  • Review
  • Open Access
4 Citations
3,703 Views
12 Pages

20 July 2024

The development and growth of cancer is fundamentally dependent on pro-tumor changes in metabolism. Cancer cells generally shift away from oxidative phosphorylation as the primary source of energy and rely more heavily on glycolysis. Receptor tyrosin...

(This article belongs to the Section Molecular Genetics and Genomics)
  • Review
  • Open Access
13 Citations
8,800 Views
13 Pages

c-Met and miRs in Cancer

  • Simona Giglio and
  • Andrea Vecchione

c-Met, a member of the receptor tyrosine kinase family, is involved in a wide range of cellular processes, including tumor survival, cell growth, angiogenesis and metastasis, and resulting in overexpression in many human cancers, leading to a constit...

(This article belongs to the Special Issue New aspects of the Hepatocyte Growth Factor/c-Met System)
  • Article
  • Open Access
33 Citations
10,210 Views
13 Pages

VHH-Photosensitizer Conjugates for Targeted Photodynamic Therapy of Met-Overexpressing Tumor Cells

  • Raimond Heukers,
  • Vida Mashayekhi,
  • Mercedes Ramirez-Escudero,
  • Hans de Haard and ,
  • Theo C. Verrips,
  • Paul. M.P. van Bergen en Henegouwen and
  • Sabrina Oliveira
  • + 2 authors+ 0 author

Photodynamic therapy (PDT) is an approach that kills (cancer) cells by the local production of toxic reactive oxygen species upon the local illumination of a photosensitizer (PS). The specificity of PDT has been further enhanced by the development of...

(This article belongs to the Special Issue Nanobody)
  • Review
  • Open Access
93 Citations
11,687 Views
17 Pages

3 December 2018

Hepatocyte growth factor (HGF)/ mesenchymal-epithelial transition factor (c-MET) signaling is involved in complex cellular programs that are important for embryonic development and tissue regeneration, but its activity is also utilized by cancer cell...

(This article belongs to the Special Issue Hepatocyte Growth Factor (HGF))
  • Review
  • Open Access
27 Citations
8,461 Views
18 Pages

25 January 2024

Brain tumors represent a heterogeneous group of neoplasms characterized by a high degree of aggressiveness and a poor prognosis. Despite recent therapeutic advances, the treatment of brain tumors, including glioblastoma (GBM), an aggressive primary b...

(This article belongs to the Special Issue Novel Therapeutic Strategies for the Treatment of Brain Tumors)
  • Article
  • Open Access
11 Citations
4,568 Views
16 Pages

New Preclinical Development of a c-Met Inhibitor and Its Combined Anti-Tumor Effect in c-Met-Amplified NSCLC

  • Nam Ah Kim,
  • Sungyoul Hong,
  • Ki Hyun Kim,
  • Du Hyung Choi and ,
  • Joo Seok Kim,
  • Kyung Eui Park,
  • Jun Young Choi,
  • Young Kee Shin and
  • Seong Hoon Jeong
  • + 4 authors+ 0 author

c-Met is a receptor tyrosine kinase with no commercially available product despite being a pivotal target in cancer progression. Unlike other c-Met inhibitors that fail clinically, ABN401 is a newly synthesized c-Met inhibitor that is not potentially...

(This article belongs to the Special Issue Bioavailability Enhancement of Poorly Water-Soluble Drugs: Biopharmaceutics and Technology)
  • Review
  • Open Access
33 Citations
5,287 Views
15 Pages

The Role of HGF/MET Signaling in Metastatic Uveal Melanoma

  • Ryota Tanaka,
  • Mizue Terai,
  • Eric Londin and
  • Takami Sato

30 October 2021

Hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (MET) signaling promotes tumorigenesis and tumor progression in various types of cancer, including uveal melanoma (UM). The roles of HGF/MET signaling have been studied in cell s...

(This article belongs to the Special Issue Metastatic Uveal Melanoma)
  • Article
  • Open Access
1 Citations
1,711 Views
15 Pages

Phosphorylation of MET Is Upregulated in Metastatic Sites of Renal Cell Carcinoma: Possible Role of MET and Hepatocyte Growth Factor Activation-Targeted Combined Therapy

  • Takahiro Akioka,
  • Shoichi Kimura,
  • Yuichi Katayama,
  • Masato Fujii and ,
  • Takumi Kiwaki,
  • Makiko Kawaguchi,
  • Tsuyoshi Fukushima,
  • Yuichiro Sato,
  • Shoichiro Mukai and
  • Atsuro Sawada
  • + 6 authors+ 1 author

Background: Increased expression of MET and hepatocyte growth factor (HGF)-related molecules has been positively correlated with poor prognosis in renal cell carcinoma (RCC). In the current study, the expression and phosphorylation of MET in metastat...

(This article belongs to the Section Cancer Biology and Oncology)
  • Feature Paper
  • Article
  • Open Access
538 Views
13 Pages

The Influence of Catechol-O-Methyltransferase Val158Met Polymorphism in Cognitive Performance and Executive Functioning in Women with Migraine

  • Margarita Cigarán-Méndez,
  • Ana I. de-la-Llave-Rincón,
  • Juan C. Pacho-Hernández,
  • Angela Tejera-Alonso and ,
  • Cristina Gómez-Calero,
  • César Fernández-de-las-Peñas and
  • Silvia Ambite-Quesada
  • + 2 authors+ 0 author

11 June 2026

Background/Objectives: No study has investigated the effect of the catechol-O-methyltransferase (COMT) Val158Met rs4680 polymorphism in cognitive and executive performance in migraine. The current study investigated the potential influence of the Val...

(This article belongs to the Section Clinical Neurology)
  • Review
  • Open Access
9 Citations
7,176 Views
22 Pages

MET Activation in Lung Cancer and Response to Targeted Therapies

  • Sarah Anna Okun,
  • Daniel Lu,
  • Katherine Sew,
  • Asha Subramaniam and
  • William W. Lockwood

16 January 2025

The hepatocyte growth factor receptor (MET) is a receptor tyrosine kinase (RTK) that mediates the activity of a variety of downstream pathways upon its activation. These pathways regulate various physiological processes within the cell, including gro...

(This article belongs to the Special Issue New and Emerging Strategies for Targeting Genomic Instability and Overcoming Drug Resistance in Lung Cancer)
  • Article
  • Open Access
604 Views
15 Pages

Influence of Catechol-O-Methyltransferase (COMT) Val158Met Polymorphism in Conditioned Pain Modulation in Women with Migraine

  • Margarita Cigarán-Méndez,
  • Ana I. de-la-Llave-Rincón,
  • Juan C. Pacho-Hernández,
  • Angela Tejera-Alonso and ,
  • Cristina Gómez-Calero,
  • César Fernández-de-las-Peñas,
  • Lars Arendt-Nielsen and
  • Silvia Ambite-Quesada
  • + 3 authors+ 0 author

The role of the catechol-O-methyltransferase (COMT) Val158Met rs4680 polymorphism in altered pain processing in headaches is controversial. The aim of this study was to investigate the influence of the Val158Met rs4680 polymorphism in conditioned pai...

(This article belongs to the Section Molecular Neurobiology)
  • Review
  • Open Access
9 Citations
5,584 Views
26 Pages

The MET Oncogene Network of Interacting Cell Surface Proteins

  • Simona Gallo,
  • Consolata Beatrice Folco and
  • Tiziana Crepaldi

21 December 2024

The MET oncogene, encoding the hepatocyte growth factor (HGF) receptor, plays a key role in tumorigenesis, invasion, and resistance to therapy, yet its full biological functions and activation mechanisms remain incompletely understood. A feature of M...

(This article belongs to the Special Issue Latest Review Papers in Molecular and Cellular Biology 2024)
  • Review
  • Open Access
25 Citations
6,253 Views
13 Pages

26 March 2023

Gastric cancer (GC) is an important cause of cancer worldwide with over one million new cases yearly. The vast majority of cases present in stage IV disease, and it still bears a poor prognosis. However, since 2010, progress has been made with the in...

(This article belongs to the Special Issue Roles of MET in Cancer Development and Treatment)
  • Article
  • Open Access
8 Citations
3,993 Views
12 Pages

15 July 2022

Both MET exon 14 skipping mutation (METex14SM) and high copy-number variation (CNV) lead to enhanced carcinogenesis; additionally, programmed-death ligand 1 (PD-L1) is often upregulated in cancers. In this study, we characterized the expression of ME...

(This article belongs to the Section Cancer Pathophysiology)
  • Review
  • Open Access
1,065 Views
71 Pages

Medicinal Chemistry of Small-Molecule c-Met Inhibitors: From Approved Therapies to Emerging Multitarget Anticancer Agents

  • Siva S. Panda,
  • Mohamed S. Bekheit,
  • Dalia R. Aboshouk,
  • Sudhan Sivakumar and ,
  • Mohamed A. Morsy,
  • Mariam Abdur-Rahman,
  • Abdelgawad Fahmi and
  • Adel S. Girgis
  • + 3 authors+ 0 author

9 September 2026

The hepatocyte growth factor (HGF)/c-Met signaling pathway plays a central role in cellular proliferation, survival, migration, invasion, angiogenesis, and therapeutic resistance. Aberrant c-Met activation, driven by gene amplification, overexpressio...

(This article belongs to the Special Issue Structure-Based Design of Drugs and Other Bioactive Molecules)
  • Article
  • Open Access
5 Citations
2,780 Views
16 Pages

Newly Established Genetic System for Functional Analysis of MetSV

  • Finn O. Gehlert,
  • Katrin Weidenbach,
  • Brian Barüske,
  • Daniela Hallack and ,
  • Urska Repnik and
  • Ruth A. Schmitz
  • + 1 author+ 0 author

The linear chromosome of the Methanosarcina spherical virus with 10,567 bp exhibits 22 ORFs with mostly unknown functions. Annotation using common tools and databases predicted functions for a few genes like the type B DNA polymerase (MetSVORF07) or...

(This article belongs to the Section Molecular Microbiology)
  • Review
  • Open Access
46 Citations
8,977 Views
17 Pages

HGF/c-MET: A Promising Therapeutic Target in the Digestive System Cancers

  • Hongli Zhang,
  • Qingqing Feng,
  • Wei-Dong Chen and
  • Yan-Dong Wang

23 October 2018

The HGF/c-MET pathway is active in the development of digestive system cancers, indicating that inhibition of HGF/c-MET signaling may have therapeutic potential. Various HGF/c-MET signaling inhibitors, mainly c-MET inhibitors, have been tested in cli...

(This article belongs to the Special Issue Hepatocyte Growth Factor (HGF))
  • Article
  • Open Access
4 Citations
2,625 Views
15 Pages

SMYD3 Modulates the HGF/MET Signaling Pathway in Gastric Cancer

  • Katia De Marco,
  • Martina Lepore Signorile,
  • Elisabetta Di Nicola,
  • Paola Sanese and ,
  • Candida Fasano,
  • Giovanna Forte,
  • Vittoria Disciglio,
  • Antonino Pantaleo,
  • Greta Varchi and
  • Cristiano Simone
  • + 7 authors+ 2 authors

18 October 2023

Gastric cancer (GC) is the third most deadly cancer worldwide. Considerable efforts have been made to find targetable drivers in order to improve patient outcomes. MET is one of the most important factors involved in GC initiation and progression as...

(This article belongs to the Section Tissues and Organs)

of 594